Dr.PainCLE said:Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction…
My labs after 12 months on glycaemic control: A1C 5.4%, fasting glucose 94 mg/dL, fasting insulin 5 uIU/mL. My endo says these are "textbook perfect."
For context, my baseline A1C was 8.3% and fasting glucose was 129 mg/dL. The improvement has been dramatic and consistent.
pete_manc_UK said:Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:
| Test | Baseline | Month 3 | Month 6 | Month 12 |
|---|---|---|---|---|
| Glucose (fasting) | 127 | 105 | 91 | 83 |
| Insulin (fasting) | 23 | 13 | 11 | 6 |
| HOMA-IR | 5.5 | 3.8 | 1.9 | 1.1 |
| Uric Acid | 8.5 | 6.7 | 5.8 | 4.8 |
The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 5.5 to near 1.0 is a metabolic transformation.
LarryQC_SD said:My labs after 12 months on glycaemic control: A1C 5.4%, fasting glucose 94 mg/dL, fasting insulin 5 uIU/mL.
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 40% to 20%. Target is <36%, with <30% being ideal.
Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemOne thing that is still open after jim_asheville’s answer:
What did you change at the same time, and can you separate the two now?
Dr.EndoIndy said:Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 40% to 20%.
PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.
After 12 months: periods became regular for the first time in ever, testosterone levels normalized, acne cleared significantly, and — unexpectedly — my hormonal symptoms have almost completely resolved.
GLP-1 agonists address the insulin resistance at the root of PCOS. For PCOS patients, this isn't "just" a weight loss drug — it's treating our underlying metabolic dysfunction.